The cost study of treating mCRC with bevacizumab plus chemotherapy in the real clinical practice in the Czech Republic
| Autoři | |
|---|---|
| Rok publikování | 2012 |
| Druh | Konferenční abstrakty |
| Citace | |
| Popis | Bevacizumab, a humanized monoclonal IgG antibody against the vascular endothelial growth factor (VEGF), is reimbursed in the Czech Republic in combination with chemotherapy for the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, its high cost is a potentially limiting factor. |